Rivka Schwartz - Compugen VP Discovery

CGEN Stock  ILA 580.00  6.10  1.04%   

Insider

Rivka Schwartz is VP Discovery of Compugen
Phone(972) 3 765 8555
Webwww.cgen.com

Compugen Management Efficiency

The company has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.
100%
Compugen has accumulated 2.85 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Compugen has a current ratio of 9.41, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Compugen until it has trouble settling it off, either with new capital or with free cash flow. So, Compugen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Compugen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Compugen to invest in growth at high rates of return. When we think about Compugen's use of debt, we should always consider it together with cash and equity.
D...Cash97.48%100%

Similar Executives

Showing other executives

INSIDER Age

Yaron EldadEvogene
58
Shachar CPAEnlivex Therapeutics
46
Isaac IsraelPurple Biotech
45
John LaceyBioLine RX
N/A
Abi MDBioLine RX
47
Dotan BorensteinEvogene
N/A
Liron MBABioLine RX
N/A
Bertrand LiangPurple Biotech
60
Odelia BenShitritEnlivex Therapeutics
N/A
Iris SadehClal Biotechnology Industries
N/A
Arnon MDClal Biotechnology Industries
54
Elran MBAEvogene
43
Liat NissanClal Biotechnology Industries
N/A
Michel HabibEnlivex Therapeutics
52
Raziel FriedBioLine RX
N/A
Michael SchicklerPurple Biotech
65
Sigal AradEnlivex Therapeutics
N/A
Etty KligerClal Biotechnology Industries
N/A
Gil CPAPurple Biotech
57
CPA MBABioLine RX
62
CPA MBAPurple Biotech
72
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 68 people. Compugen (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 73 people.

Management Performance

Compugen Leadership Team

Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alberto Sessa, Chief Officer
Michal Preminger, Director
Rivka Schwartz, VP Discovery
Paul Sekhri, Chairman of the Board
Henry MD, VP Officer
Arie Ovadia, Independent External Director
Zurit Levine, Vice President - Research and Discovery
Eran Perry, Director
Ari Krashin, Chief Financial Officer
Sanford Zweifach, Director
Gilead Halevy, Director
Anat CohenDayag, President, Chief Executive Officer, Director
Ruth Arnon, Independent Director
Yvonne Naughton, Head Communications
Kinneret Savitsky, Director
Henry Adewoye, Chief Medical Officer
Dorit Amitay, VP HR
Yair Aharonowitz, Independent External Director
Eran Dor, Gen Sec
JeanPierre Bizzari, Director
Oliver Froescheis, Sr Devel
John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc

Compugen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Compugen Stock

When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Compugen Stock refer to our How to Trade Compugen Stock guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…